Drug Profile
Research programme: antibody therapeutics - Lexicon/XOMA
Latest Information Update: 13 Feb 2014
Price :
$50
*
At a glance
- Originator Lexicon Pharmaceuticals
- Developer Lexicon Pharmaceuticals; XOMA
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders